{
    "clinical_study": {
        "@rank": "87209", 
        "arm_group": {
            "arm_group_label": "Intensity-modulated radiotherapy (IMRT)", 
            "arm_group_type": "Experimental", 
            "description": "1. 3 dimensional conformal radiotherapy of whole pelvis \u00b1 Para-aortic lymphatics, inguinal lymphatics\nT2a under: 45 Gy/25 fx\nT2b over: 50.4 Gy/28 fx * Fraction size = 1.8 Gy or 2 Gy\n2. IMRT boost of gross LNs\nTomotherapy fraction size (Gy) = 0.4 x diagnosis of LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)\nTotal dose(summation dose with 3D-CRT) (Gy10) (EQD2, \u03b1/\u03b2=10 Gy) = 5 x diagnosis of LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
        }, 
        "brief_summary": {
            "textblock": "This phase II study of high dose intensity modulated radiation therapy in the cervical\n      cancer with metastatic lymphadenopathies at initial diagnosis"
        }, 
        "brief_title": "A Phase II Study of High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies at Initial Diagnosis", 
        "condition": "Cervical Cancer With Metastatic Lymphadenopathies at Initial Diagnosis", 
        "condition_browse": {
            "mesh_term": [
                "Uterine Cervical Neoplasms", 
                "Lymphatic Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients (who have been adequately clinically staged) with primary, untreated,\n             histologically confirmed carcinoma of the uterine cervix (including clear cell and\n             small cell carcinoma), with metastatic lymphadenopathies (any of pelvis or PAN >1.5\n             cm in short diameter, with/without biopsy proven inguinal lymph node [ING])\n\n          2. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, 2\n\n          3. Patients with adequate bone marrow function: absolute neutrophil count (ANC) greater\n             than or equal to 1,500/mcl, platelets greater than or equal to 100,000/mcl at the\n             beginning.\n\n          4. Patients with adequate renal function: creatinine equal to or less than 2.0 mg%.\n\n          5. Patients who have signed an approved informed consent and authorization\n\n        Exclusion Criteria:\n\n          1. Patients with recurrent LN(s) which was(were) previously irradiated.\n\n          2. Patients who have diagnosis of other malignance tumors except papillary or follicular\n              thyroid cancer or skin cancer\n\n          3. Patients with metastatic lymphadenopathies other than pelvis, PAN, ING (e.g.\n             supraclavicular or mediastinal metastatic lymphadenopathy)\n\n          4. Patients with distant organ metastasis (e.g. bone, lung, brain\u2026)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730651", 
            "org_study_id": "NCCCTS 12-615"
        }, 
        "intervention": {
            "arm_group_label": "Intensity-modulated radiotherapy (IMRT)", 
            "intervention_name": "Intensity-modulated radiation therapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "cervical cancer with metastatic lymphadenopathies at initial diagnosis", 
        "lastchanged_date": "November 15, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Goyang-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "410-769"
                    }, 
                    "name": "National Cancer Center, Korea"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang-si,", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "411-769"
                    }, 
                    "name": "National Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies at Initial Diagnosis", 
        "other_outcome": {
            "description": "\u2460 Acute: gastrointestinal (GI), genitourinary (GU), bone marrow (BM)\n\u2461 Late: GI, GU, lower extremity edema, treatment-related neuropathy, bone density change", 
            "measure": "Toxicity", 
            "safety_issue": "No", 
            "time_frame": "every follow-up date, up to 3 years"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Center, Korea", 
            "last_name": "Jooyoung Kim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "From date of initiation of radiotherapy until the date of documented date of death from any cause, assessed up to 3 years", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "documented data of death, up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730651"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Center, Korea", 
            "investigator_full_name": "Joo-Young Kim", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "From date of initiation of radiotherapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.\nProgression-free survival of lymph nodes(LNs) treated with high dose \u2461 Regional LN (other than the LNs treated with high dose) failure-free survival \u2462 Distant organ (other than para-aortic LNs[PAN]) failure-free survival", 
            "measure": "Disease-free survival (DFS)", 
            "safety_issue": "No", 
            "time_frame": "documented date of progression or death, up to 3 years"
        }, 
        "source": "National Cancer Center, Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Center, Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}